

01-03-02

**CERTIFICATE OF MAILING (37 CFR 1.10)**

"Express Mail" No: EL742262275 US

Date of Deposit: December 28, 2001

I hereby certify that this transmittal together with the patent application referred to below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Julie K. Lyons, Legal Assistant

Julie K. Lyons

Name of Person Mailing Paper

Signature

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Commissioner of Patents and Trademarks  
Washington, DC 20231

**TRANSMITTAL OF A NON-PROVISIONAL APPLICATION  
Under 37 CFR 1.53(b)(1)**

Sir,

Transmitted herewith for filing is the patent application entitled New Drug Combination.

- ☒ This application is being mailed by Express Mail under 37 CFR 1.10 and the required certificate appears above.
- ☐ The Oath or Declaration required under 37 CFR 1.63 is **being transmitted** with this application.
- ☒ The Oath or Declaration required under 37 CFR 1.63 is **not being transmitted** with this application pursuant to 37 CFR 1.53(f).
- ☐ A disk containing nucleotide and/or amino acid sequences in a computer readable format is attached. The contents of the sequence listing in the application is the same as the document on the disk. (37 CFR 1.821(f) and MPEP 2422.06)

The filing fee has been calculated as shown below:

	Total No. of Claims	No. of Claims Without Additional Fee	Excess Claims	\$ Rate	Fee
Total Claims Fee	22	20	2	x 18	36
Independent Claims Fee	5	3	2	x 84	168
Multiple Dependent Claim	0			x 280	0
Basic Fee					740
Total Filing Fee					\$ 944

- ☒ **SPECIFIC DEPOSIT ACCOUNT AUTHORIZATION.** Please charge my Deposit Account No. 21-0718 in the amount of the total filing fee above. Triplicate copies of this sheet are enclosed.
- ☒ **GENERAL DEPOSIT ACCOUNT AUTHORIZATION.** The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or during the pendency of this application or credit any overpayment to Deposit Account No. 21-0718.

- (1) Any additional filing fees or fees for the presentation of additional claims required under 37 CFR 1.16.

(2) Any patent application processing fees under 37 CFR 1.17.

No authorization is given to charge the Issue Fee (37 CFR 1.18).

[ ] **ASSIGNMENT RECORDAL DEPOSIT ACCOUNT AUTHORIZATION.** Please charge my Deposit Account No. 21-0718 in the amount of \$40.00 for recordal for the attached assignment of the invention to Pharmacia & Upjohn Company. A separate cover sheet for assignment accompanying a new patent application is also attached.

This application is being made, or is authorized to be made, by the inventor(s) as set forth on the attached Inventor Information Sheet. The person or persons listed are believed to be the original, first and sole inventor (if only one name is listed on the attached Inventor Information Sheet) or original, first and joint inventor (if plural names are listed on the attached Inventor Information Sheet) of the subject matter which is claimed and for which a patent is sought.

The undersigned hereby requests that all correspondence in connection with this application be directed to

[X] the address associated with Customer Number



or

25533

PATENT AND TRADEMARK OFFICE

[ ] the address below.

All telephone communications should be directed to the undersigned practitioner at the telephone number(s) indicated below.

Respectfully submitted,

Date: 12/16/01

Stephen L. Nesbitt, Attorney  
Registration No. 28,981

Pharmacia & Upjohn Company  
Global Intellectual Property  
301 Henrietta Street  
Kalamazoo, Michigan 49001

Telephone No. (616) 833-1837 or (616) 833-9500  
Telefax No. (616) 833-8897 or (616) 833-2316

Enclosures:

- [X] Patent Application
- [ ] Declaration (37 CFR 1.63) and Power of Attorney
- [ ] Assignment with Cover Page
- [ ] Disk containing Nucleotide and/or amino Acid Sequence Listing
- [X] Return Post Card

## APPLICATION DATA SHEET

### Inventor Information

Full name of sole or first inventor:

Erik Ho Fong Wong

Address:

7352 Hampstead Lane  
Portage, Michigan 49024

Citizenship:

USA

Full name of second inventor:

Christopher C. Gallen

Address:

8 Overbrook Parkway  
Wynnewood, Pennsylvania 19096

Citizenship:

USA

Full name of third inventor:

Torgny Svensson

Address:

Ringvägen 9,  
181 33 Lidingö, Sweden

Citizenship:

Sweden

### Representative Information

Representative Designation:	Registration Number:	Representative Name:
<i>Primary or Associate</i>	<i>No more than 5 digits</i>	<i>No more than 50 characters</i>
Primary	30731	Carl W. Battle
Primary	33673	James D. Darnley, Jr.
Primary	27231	Bruce Stein
Primary	35004	Thomas A. Wootton
Primary	40259	Lucy X. Yang
Primary	32175	Andrew M. Solomon
Primary	34703	Edward F. Rehberg
Primary	28075	John H. Engelmann
Primary	48061	Austin W. Zhang
Primary	28981	Stephen L. Nesbitt
Primary	48324	Mary J. Hosley
Associate	34055	Ellen Park
Associate	32748	Bruce A. Pokras

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Erik Ho Fong Wong, et al.

Docket No.

00378.US1 (PC024976)

Serial No.

10/035,100

Filing Date

28-Dec-2001

Examiner

Phyllis G. Spivack

Group Art

1614

Invention:

NEW DRUG COMBINATIONS OF NOREPINEHRINE REUPTAKE INHIBITORS AND NEUROLEPTIC AGENTS

I hereby certify that this

Amendment and Response with Information Disclosure Statement*(Identify type of correspondence)*

Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231

on

December 18, 2003  
*(Date)*

Linda A. Zerby

*(Typed or Printed Name of Person Mailing Correspondence)*  
*(Signature of Person Mailing Correspondence)*

EU807929741 US

*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing****EXPRESS MAIL NO. EU807929741US**  
**DOCKET NO. 00378.US1 (PC24976)**